Work

Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.tps2077

Authors: David A. Reardon, Jorg Dietrich, Thomas Joseph Kaley, Hui Kong Gan, Gavin P Dunn, Timothy Francis Cloughesy, Michael Lim, Jennifer Leigh Clarke, Andrew J. Park, Linda S. Pan, Dominic W Lai, Joyson Joseph Karakunnel, Paul B. Robbins, Rajesh Narwal, Ralph Rudolph Venhaus

Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Austin Health, Washington University in St. Louis, University of California, Los Angeles, Johns Hopkins Hospital, University of California, San Francisco, Ludwig Cancer Research

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2602584329

Cites:

Cited by: 3

Related to: 10